DVAX Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2024-04-11 | 2023 | David F. Novack President and Chief Operating Officer | 570,296 | 0 | 885,125 | 427,722 | 15,563 | 2,993,331 |
| 2024-04-11 | 2022 | David F. Novack President and Chief Operating Officer | 545,738 | 0 | 645,540 | 366,736 | 13,124 | 2,779,823 |
| 2024-04-11 | 2021 | David F. Novack President and Chief Operating Officer | 519,750 | 0 | 935,025 | 436,590 | 13,635 | 2,918,100 |
| 2024-04-11 | 2021 | Kelly MacDonald Senior Vice President and Chief Financial Officer | 312,500 | 15,000 | 0 | 221,875 | 4,042 | 2,804,337 |
| 2024-04-11 | 2023 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President | 521,434 | 0 | 438,000 | 325,896 | 14,193 | 1,883,323 |
| 2024-04-11 | 2022 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President | 500,176 | 0 | 316,680 | 277,598 | 11,983 | 1,710,780 |
| 2024-04-11 | 2021 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President | 480,938 | 0 | 534,300 | 329,443 | 6,793 | 1,925,564 |
| 2024-04-11 | 2023 | Kelly MacDonald Senior Vice President and Chief Financial Officer | 475,000 | 0 | 547,500 | 301,625 | 11,930 | 2,065,805 |
| 2024-04-11 | 2022 | Kelly MacDonald Senior Vice President and Chief Financial Officer | 425,000 | 0 | 389,760 | 240,550 | 8,716 | 1,793,266 |
| 2024-04-11 | 2023 | Ryan Spencer Chief Executive Officer and Director | 760,000 | 0 | 2,281,250 | 712,500 | 13,686 | 5,810,736 |
| 2024-04-11 | 2022 | Ryan Spencer Chief Executive Officer and Director | 695,000 | 0 | 1,522,500 | 544,880 | 11,355 | 5,594,000 |
| 2024-04-11 | 2021 | Ryan Spencer Chief Executive Officer and Director | 600,000 | 0 | 1,605,608 | 588,000 | 5,431 | 4,519,489 |
| 2023-04-13 | 2022 | Ryan Spencer Chief Executive Officer and Director | 695,000 | 0 | 1,522,500 | 544,880 | 11,355 | 5,594,000 |
| 2023-04-13 | 2021 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President | 480,938 | 0 | 534,300 | 329,443 | 6,793 | 1,925,564 |
| 2023-04-13 | 2020 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President | 466,930 | 0 | 135,500 | 256,345 | 2,000 | 1,242,671 |
| 2023-04-13 | 2022 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President | 500,176 | 0 | 316,680 | 277,598 | 11,983 | 1,710,780 |
| 2023-04-13 | 2021 | Kelly MacDonald Senior Vice President and Chief Financial Officer | 312,500 | 15,000 | 0 | 221,875 | 4,042 | 2,804,337 |
| 2023-04-13 | 2022 | Kelly MacDonald Senior Vice President and Chief Financial Officer | 425,000 | 0 | 389,760 | 240,550 | 8,716 | 1,793,266 |
| 2023-04-13 | 2020 | David F. Novack President and Chief Operating Officer | 495,000 | 0 | 189,700 | 302,198 | 2,000 | 1,512,640 |
| 2023-04-13 | 2021 | David F. Novack President and Chief Operating Officer | 519,750 | 0 | 935,025 | 436,590 | 13,635 | 2,918,100 |
| 2023-04-13 | 2022 | David F. Novack President and Chief Operating Officer | 545,738 | 0 | 645,540 | 366,736 | 13,124 | 2,779,823 |
| 2023-04-13 | 2020 | Ryan Spencer Chief Executive Officer and Director | 515,000 | 0 | 206,451 | 342,990 | 2,000 | 1,521,779 |
| 2023-04-13 | 2021 | Ryan Spencer Chief Executive Officer and Director | 600,000 | 0 | 1,605,608 | 588,000 | 5,431 | 4,519,489 |
| 2022-04-14 | 2019 | David F. Novack President and Chief Operating Officer | 465,886 | 0 | 272,220 | 229,382 | 2,000 | 2,670,850 |
| 2022-04-14 | 2021 | Kelly MacDonald Senior Vice President and Chief Financial Officer | 312,500 | 15,000 | 0 | 221,875 | 4,042 | 2,804,337 |
| 2022-04-14 | 2021 | Michael S. Ostrach Former Senior Vice President, Chief Financial Officer and Chief Business Officer | 77,626 | 0 | 534,300 | 0 | 650,711 | 1,994,399 |
| 2022-04-14 | 2020 | Michael S. Ostrach Former Senior Vice President, Chief Financial Officer and Chief Business Officer | 464,398 | 0 | 135,500 | 254,955 | 2,000 | 1,238,749 |
| 2022-04-14 | 2019 | Michael S. Ostrach Former Senior Vice President, Chief Financial Officer and Chief Business Officer | 450,872 | 0 | 230,340 | 209,665 | 2,000 | 1,504,310 |
| 2022-04-14 | 2021 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 480,938 | 0 | 534,300 | 329,443 | 6,793 | 1,925,564 |
| 2022-04-14 | 2020 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 466,930 | 0 | 135,500 | 256,345 | 2,000 | 1,242,671 |
| 2022-04-14 | 2019 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 453,330 | 0 | 272,220 | 210,798 | 2,000 | 1,660,950 |
| 2022-04-14 | 2021 | Ryan Spencer Chief Executive Officer and Director | 600,000 | 0 | 1,605,608 | 588,000 | 5,431 | 4,519,489 |
| 2022-04-14 | 2020 | Ryan Spencer Chief Executive Officer and Director | 515,000 | 0 | 206,451 | 342,990 | 2,000 | 1,521,779 |
| 2022-04-14 | 2019 | Ryan Spencer Chief Executive Officer and Director | 391,212 | 0 | 654,375 | 152,375 | 2,000 | 3,157,482 |
| 2022-04-14 | 2021 | David F. Novack President and Chief Operating Officer | 519,750 | 0 | 935,025 | 436,590 | 13,635 | 2,918,100 |
| 2022-04-14 | 2020 | David F. Novack President and Chief Operating Officer | 495,000 | 0 | 189,700 | 302,198 | 2,000 | 1,512,640 |
| 2021-04-16 | 2019 | Michael S. Ostrach Former Senior Vice President, Chief Financial Officer and Chief Business Officer | 450,872 | 0 | 230,340 | 209,665 | 2,000 | 1,504,310 |
| 2021-04-16 | 2020 | Ryan Spencer Chief Executive Officer and Director | 515,000 | 0 | 206,451 | 342,990 | 2,000 | 1,521,779 |
| 2021-04-16 | 2019 | Ryan Spencer Chief Executive Officer and Director | 391,212 | 0 | 654,375 | 152,375 | 2,000 | 3,157,482 |
| 2021-04-16 | 2018 | Michael S. Ostrach Former Senior Vice President, Chief Financial Officer and Chief Business Officer | 439,875 | 0 | 0 | 216,639 | 2,000 | 3,562,514 |
| 2021-04-16 | 2020 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 466,930 | 0 | 135,500 | 256,345 | 2,000 | 1,242,671 |
| 2021-04-16 | 2019 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 453,330 | 0 | 272,220 | 210,798 | 2,000 | 1,660,950 |
| 2021-04-16 | 2018 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 438,000 | 0 | 0 | 216,810 | 2,000 | 1,739,810 |
| 2021-04-16 | 2020 | David F. Novack President and Chief Operating Officer | 495,000 | 0 | 189,700 | 302,198 | 2,000 | 1,512,640 |
| 2021-04-16 | 2019 | David F. Novack President and Chief Operating Officer | 465,886 | 0 | 272,220 | 229,382 | 2,000 | 2,670,850 |
| 2021-04-16 | 2018 | David F. Novack President and Chief Operating Officer | 401,700 | 0 | 0 | 210,892 | 2,000 | 1,697,592 |
| 2021-04-16 | 2020 | Michael S. Ostrach Former Senior Vice President, Chief Financial Officer and Chief Business Officer | 464,398 | 0 | 135,500 | 254,955 | 2,000 | 1,238,749 |
| 2020-04-17 | 2018 | Eddie Gray Former Chief Executive Officer and Director | 621,000 | 0 | 0 | 335,340 | 2,000 | 4,748,840 |
| 2020-04-17 | 2019 | Eddie Gray Former Chief Executive Officer and Director | 375,795 | 0 | 732,900 | 0 | 3,727,518 | 9,227,662 |
| 2020-04-17 | 2019 | Ryan Spencer Chief Executive Officer and Director | 391,212 | 0 | 654,375 | 152,375 | 2,000 | 3,157,482 |
| 2020-04-17 | 2019 | David F. Novack President and Chief Operating Officer | 465,886 | 0 | 272,220 | 229,382 | 2,000 | 2,670,850 |
| 2020-04-17 | 2019 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 453,330 | 0 | 272,220 | 210,798 | 2,000 | 1,660,950 |
| 2020-04-17 | 2018 | David F. Novack President and Chief Operating Officer | 401,700 | 0 | 0 | 210,892 | 2,000 | 1,697,592 |
| 2020-04-17 | 2019 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 450,872 | 0 | 230,340 | 209,665 | 2,000 | 1,504,310 |
| 2020-04-17 | 2018 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 439,875 | 0 | 0 | 216,639 | 2,000 | 3,562,514 |
| 2020-04-17 | 2018 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 438,000 | 0 | 0 | 216,810 | 2,000 | 1,739,810 |
| 2020-04-17 | 2019 | Robert L. Coffman, Ph.D. Former Senior Vice President and Chief Scientific Officer | 455,849 | 0 | 230,340 | 0 | 522,791 | 1,830,387 |
| 2020-04-17 | 2018 | Robert L. Coffman, Ph.D. Former Senior Vice President and Chief Scientific Officer | 483,134 | 0 | 0 | 239,151 | 2,000 | 3,628,285 |
| 2019-04-22 | 2018 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 439,875 | 0 | 0 | 216,639 | 2,000 | 3,562,514 |
| 2019-04-22 | 2017 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 466,796 | 0 | 1,223,041 | 297,582 | 2,000 | 1,989,419 |
| 2019-04-22 | 2016 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 466,796 | 0 | 0 | 0 | 2,000 | 1,172,548 |
| 2019-04-22 | 2018 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs | 438,000 | 0 | 0 | 216,810 | 2,000 | 1,739,810 |
| 2019-04-22 | 2016 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs | 400,000 | 0 | 0 | 0 | 2,000 | 1,072,240 |
| 2019-04-22 | 2017 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs | 400,000 | 0 | 1,068,056 | 260,000 | 2,000 | 1,730,056 |
| 2019-04-22 | 2017 | Eddie Gray CEO and Director | 600,000 | 0 | 2,094,113 | 450,000 | 2,000 | 3,146,113 |
| 2019-04-22 | 2018 | Eddie Gray CEO and Director | 621,000 | 0 | 0 | 335,340 | 2,000 | 4,748,840 |
| 2019-04-22 | 2016 | David F. Novack Senior Vice President, Operations and Quality | 386,250 | 0 | 0 | 0 | 2,000 | 924,442 |
| 2019-04-22 | 2018 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 483,134 | 0 | 0 | 239,151 | 2,000 | 3,628,285 |
| 2019-04-22 | 2016 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 425,000 | 0 | 0 | 0 | 2,000 | 1,130,752 |
| 2019-04-22 | 2017 | David F. Novack Senior Vice President, Operations and Quality | 386,250 | 0 | 1,036,148 | 241,406 | 2,000 | 1,665,804 |
| 2019-04-22 | 2018 | David F. Novack Senior Vice President, Operations and Quality | 401,700 | 0 | 0 | 210,893 | 2,000 | 1,697,593 |
| 2019-04-22 | 2016 | Eddie Gray CEO and Director | 600,000 | 0 | 0 | 0 | 2,000 | 2,947,840 |
| 2019-04-22 | 2017 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 425,000 | 0 | 1,126,060 | 265,625 | 2,000 | 1,818,685 |
| 2018-04-20 | 2016 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 466,796 | 0 | 0 | 0 | 2,000 | 1,172,548 |
| 2018-04-20 | 2017 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 466,796 | 0 | 1,223,041 | 297,582 | 2,000 | 1,989,419 |
| 2018-04-20 | 2015 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 390,000 | 0 | 0 | 228,150 | 2,000 | 2,040,503 |
| 2018-04-20 | 2016 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 425,000 | 0 | 0 | 0 | 2,000 | 1,130,752 |
| 2018-04-20 | 2017 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 425,000 | 0 | 1,126,060 | 265,625 | 2,000 | 1,818,685 |
| 2018-04-20 | 2015 | Eddie Gray CEO and Director | 566,500 | 0 | 0 | 370,491 | 2,000 | 3,943,607 |
| 2018-04-20 | 2016 | Eddie Gray CEO and Director | 600,000 | 0 | 0 | 0 | 2,000 | 2,947,840 |
| 2018-04-20 | 2017 | Eddie Gray CEO and Director | 600,000 | 0 | 2,094,113 | 450,000 | 2,000 | 3,146,113 |
| 2018-04-20 | 2017 | David F. Novack Senior Vice President, Operations and Quality | 386,250 | 0 | 1,036,148 | 241,406 | 2,000 | 1,665,804 |
| 2018-04-20 | 2016 | David F. Novack Senior Vice President, Operations and Quality | 386,250 | 0 | 0 | 0 | 2,000 | 924,442 |
| 2018-04-20 | 2015 | David F. Novack Senior Vice President, Operations and Quality | 375,000 | 0 | 0 | 210,000 | 2,000 | 1,588,539 |
| 2018-04-20 | 2015 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs | 369,513 | 0 | 0 | 206,928 | 2,000 | 1,326,257 |
| 2018-04-20 | 2016 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs | 400,000 | 0 | 0 | 0 | 2,000 | 1,072,240 |
| 2018-04-20 | 2017 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs | 400,000 | 0 | 1,068,056 | 260,000 | 2,000 | 1,730,056 |
| 2018-04-20 | 2015 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 453,200 | 0 | 0 | 253,792 | 2,000 | 2,009,623 |
| 2017-04-21 | 2015 | David F. Novack Senior Vice President, Operations and Quality | 375,000 | 0 | 0 | 210,000 | 2,000 | 1,588,539 |
| 2017-04-21 | 2016 | Eddie Gray CEO and Director | 600,000 | 0 | 0 | 0 | 2,000 | 2,947,840 |
| 2017-04-21 | 2015 | Eddie Gray CEO and Director | 566,500 | 0 | 0 | 370,491 | 2,000 | 3,943,607 |
| 2017-04-21 | 2014 | Eddie Gray CEO and Director | 515,000 | 0 | 855,000 | 432,600 | 0 | 5,367,509 |
| 2017-04-21 | 2016 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 425,000 | 0 | 0 | 0 | 2,000 | 1,130,752 |
| 2017-04-21 | 2015 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 390,000 | 0 | 0 | 228,150 | 2,000 | 2,040,503 |
| 2017-04-21 | 2014 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 354,152 | 0 | 181,000 | 221,345 | 0 | 1,181,828 |
| 2017-04-21 | 2016 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 466,796 | 0 | 0 | 0 | 2,000 | 1,172,548 |
| 2017-04-21 | 2015 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 453,200 | 0 | 0 | 253,792 | 2,000 | 2,009,623 |
| 2017-04-21 | 2014 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 440,000 | 0 | 42,250 | 286,000 | 0 | 768,250 |
| 2017-04-21 | 2016 | Robert Janssen, M.D. Vice President and Chief Medical Officer | 400,000 | 0 | 0 | 0 | 2,000 | 1,072,240 |
| 2017-04-21 | 2015 | Robert Janssen, M.D. Vice President and Chief Medical Officer | 369,513 | 0 | 0 | 206,928 | 2,000 | 1,326,257 |
| 2017-04-21 | 2014 | Robert Janssen, M.D. Vice President and Chief Medical Officer | 358,750 | 0 | 181,000 | 246,641 | 0 | 1,069,945 |
| 2017-04-21 | 2016 | David F. Novack Senior Vice President, Operations and Quality | 386,250 | 0 | 0 | 0 | 2,000 | 924,442 |
| 2017-04-21 | 2014 | David F. Novack Senior Vice President, Operations and Quality | 309,000 | 0 | 362,000 | 208,575 | 0 | 1,226,141 |
| 2016-04-22 | 2014 | Michael S. Ostrach Senior Vice President, Chief Financial Officer and Chief Business Officer | 354,152 | 0 | 181,000 | 221,345 | 0 | 1,181,828 |
| 2016-04-22 | 2014 | David F. Novack Senior Vice President, Operations and Quality | 309,000 | 0 | 362,000 | 208,575 | 0 | 1,226,141 |
| 2016-04-22 | 2015 | David F. Novack Senior Vice President, Operations and Quality | 375,000 | 0 | 0 | 210,000 | 2,000 | 1,588,539 |
| 2016-04-22 | 2013 | Robert Janssen, M.D. Chief Medical Officer and Vice President, Clinical Development | 323,878 | 0 | 175,500 | 145,000 | 4,361 | 648,739 |
| 2016-04-22 | 2014 | Robert Janssen, M.D. Chief Medical Officer and Vice President, Clinical Development | 358,750 | 0 | 181,000 | 246,641 | 0 | 1,069,945 |
| 2016-04-22 | 2015 | Robert Janssen, M.D. Chief Medical Officer and Vice President, Clinical Development | 369,513 | 0 | 0 | 206,928 | 2,000 | 1,326,257 |
| 2016-04-22 | 2013 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 282,620 | 0 | 0 | 175,000 | 250 | 963,634 |
| 2016-04-22 | 2014 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 440,000 | 0 | 42,250 | 286,000 | 0 | 768,250 |
| 2016-04-22 | 2015 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 453,200 | 0 | 0 | 253,792 | 2,000 | 2,009,623 |
| 2016-04-22 | 2015 | Eddie Gray CEO and Director | 566,500 | 0 | 0 | 370,491 | 2,000 | 3,943,607 |
| 2016-04-22 | 2014 | Eddie Gray CEO and Director | 515,000 | 0 | 855,000 | 432,600 | 0 | 5,367,509 |
| 2016-04-22 | 2013 | Eddie Gray CEO and Director | 333,333 | 200,000 | 0 | 50,000 | 200,250 | 3,813,583 |
| 2016-04-22 | 2015 | Michael S. Ostrach Senior Vice President, Chief Financial Officer and Chief Business Officer | 390,000 | 0 | 0 | 228,150 | 2,000 | 2,040,503 |
| 2016-04-22 | 2013 | Michael S. Ostrach Senior Vice President, Chief Financial Officer and Chief Business Officer | 342,176 | 0 | 0 | 185,000 | 3,616 | 1,092,752 |
| 2016-04-22 | 2013 | David F. Novack Senior Vice President, Operations and Quality | 230,769 | 75,000 | 0 | 155,000 | 1,932 | 1,049,801 |
| 2012-04-25 | 2010 | Dino Dina, M.D., Chief Executive Officer and Director | 408,000 | 0 | 0 | 195,840 | 23,661 | 841,641 |
| 2012-04-25 | 2009 | Dino Dina, M.D., Chief Executive Officer and Director | 408,000 | 0 | 0 | 244,800 | 9,631 | 758,611 |
| 2012-04-25 | 2011 | Dino Dina, M.D., Chief Executive Officer and Director | 448,800 | 0 | 0 | 215,424 | 11,498 | 2,787,647 |
| 2011-04-20 | 2010 | Stephen F. Tuck, Ph.D. | 51,875 | 50,000 | 148,500 | 0 | 544,148 | 1,056,058 |
| 2011-04-20 | 2009 | Jennifer Lew Vice President, Finance | 200,625 | 0 | 0 | 68,063 | 130 | 280,841 |
| 2011-04-20 | 2010 | Jennifer Lew Vice President, Finance | 214,200 | 0 | 0 | 68,544 | 1,644 | 355,768 |
| 2011-04-20 | 2008 | Dino Dina, M.D. Chief Executive Officer and Director | 408,000 | 0 | 117,900 | 146,880 | 2,538 | 1,034,438 |
| 2011-04-20 | 2009 | Dino Dina, M.D. Chief Executive Officer and Director | 408,000 | 0 | 0 | 244,800 | 1,660 | 750,640 |
| 2011-04-20 | 2010 | Dino Dina, M.D. Chief Executive Officer and Director | 408,000 | 0 | 0 | 195,840 | 16,843 | 834,823 |
| 2011-04-20 | 2010 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 321,829 | 0 | 0 | 147,315 | 5,454 | 617,358 |
| 2011-04-20 | 2010 | J. Tyler Martin, M.D. | 383,000 | 0 | 0 | 157,641 | 13,808 | 1,429,212 |
| 2011-04-20 | 2009 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 305,000 | 0 | 0 | 152,500 | 3,947 | 497,515 |
| 2011-04-20 | 2008 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 281,112 | 0 | 78,600 | 118,067 | 3,511 | 715,215 |
| 2010-11-30 | 2007 | Dino Dina, M.D. President, Chief Executive Officer and Director | 400,000 | 0 | 0 | 180,000 | 2,180 | 1,608,605 |
| 2010-11-30 | 2007 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 300,000 | 0 | 0 | 105,600 | 2,079 | 407,679 |
| 2010-11-30 | 2008 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 307,000 | 0 | 78,600 | 110,520 | 3,126 | 624,006 |
| 2010-11-30 | 2009 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 307,000 | 0 | 0 | 153,500 | 32,318 | 528,886 |
| 2010-11-30 | 2009 | Jennifer Lew | 200,625 | 0 | 0 | 68,063 | 4,242 | 284,953 |
| 2010-11-30 | 2007 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 324,409 | 0 | 0 | 81,751 | 18,811 | 424,971 |
| 2010-11-30 | 2008 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 360,184 | 0 | 0 | 124,081 | 20,741 | 582,099 |
| 2010-11-30 | 2009 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 341,405 | 0 | 0 | 99,007 | 22,946 | 477,785 |
| 2010-11-30 | 2007 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 275,600 | 0 | 0 | 103,626 | 4,787 | 548,241 |
| 2010-11-30 | 2008 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 281,112 | 0 | 78,600 | 118,067 | 3,511 | 715,215 |
| 2010-11-30 | 2009 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 305,000 | 0 | 0 | 152,500 | 19,687 | 513,255 |
| 2010-11-30 | 2008 | Dino Dina, M.D. President, Chief Executive Officer and Director | 408,000 | 0 | 117,900 | 146,880 | 2,538 | 1,034,438 |
| 2010-11-30 | 2009 | Dino Dina, M.D. President, Chief Executive Officer and Director | 408,000 | 0 | 0 | 244,800 | 9,631 | 758,611 |
| 2010-03-26 | 2009 | Dino Dina, M.D. President, Chief Executive Officer and Director | 408,000 | 0 | 0 | 244,800 | 9,631 | 758,611 |
| 2010-03-26 | 2008 | Dino Dina, M.D. President, Chief Executive Officer and Director | 408,000 | 0 | 117,900 | 146,880 | 2,538 | 1,034,438 |
| 2010-03-26 | 2007 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 300,000 | 0 | 0 | 105,600 | 2,079 | 407,679 |
| 2010-03-26 | 2007 | Dino Dina, M.D. President, Chief Executive Officer and Director | 400,000 | 0 | 0 | 180,000 | 2,180 | 1,608,605 |
| 2010-03-26 | 2008 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 307,000 | 0 | 78,600 | 110,520 | 3,126 | 624,006 |
| 2010-03-26 | 2009 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 305,000 | 0 | 0 | 152,500 | 19,687 | 513,255 |
| 2010-03-26 | 2008 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 281,112 | 0 | 78,600 | 118,067 | 3,511 | 715,215 |
| 2010-03-26 | 2007 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 275,600 | 0 | 0 | 103,626 | 4,787 | 548,241 |
| 2010-03-26 | 2009 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 341,405 | 0 | 0 | 99,007 | 22,946 | 477,785 |
| 2010-03-26 | 2008 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 360,184 | 0 | 0 | 124,081 | 20,741 | 582,099 |
| 2010-03-26 | 2007 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 324,409 | 0 | 0 | 81,751 | 18,811 | 424,971 |
| 2010-03-26 | 2009 | Jennifer Lew | 200,625 | 0 | 0 | 68,063 | 4,242 | 284,953 |
| 2010-03-26 | 2009 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 307,000 | 0 | 0 | 153,500 | 32,318 | 528,886 |
| 2009-04-03 | 2006 | Deborah A. Smeltzer Chief Financial Officer and Vice President, Operations | 275,000 | 0 | 0 | 98,450 | 250 | 640,504 |
| 2009-04-03 | 2008 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 307,000 | 0 | 3,992 | 110,520 | 3,126 | 756,403 |
| 2009-04-03 | 2007 | Deborah A. Smeltzer Chief Financial Officer and Vice President, Operations | 302,500 | 0 | 0 | 108,900 | 188 | 754,870 |
| 2009-04-03 | 2008 | Deborah A. Smeltzer Chief Financial Officer and Vice President, Operations | 308,550 | 0 | 3,992 | 111,078 | 250 | 797,909 |
| 2009-04-03 | 2008 | Martin E. Sanders, M.D. | 419,811 | 0 | 0 | 0 | 188 | 765,379 |
| 2009-04-03 | 2007 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 275,600 | 0 | 0 | 103,626 | 4,787 | 594,668 |
| 2009-04-03 | 2008 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 281,112 | 0 | 3,992 | 118,067 | 3,511 | 634,176 |
| 2009-04-03 | 2006 | Dino Dina, M.D. President, Chief Executive Officer and Director | 360,000 | 0 | 0 | 148,500 | 250 | 1,321,431 |
| 2009-04-03 | 2007 | Dino Dina, M.D. President, Chief Executive Officer and Director | 400,000 | 0 | 0 | 180,000 | 2,180 | 1,611,913 |
| 2009-04-03 | 2008 | Zbigniew Janowicz, Ph.D. (8) Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 360,184 | 0 | 0 | 124,081 | 20,741 | 687,528 |
| 2009-04-03 | 2006 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 265,000 | 0 | 0 | 94,870 | 3,158 | 585,915 |
| 2009-04-03 | 2008 | Dino Dina, M.D. President, Chief Executive Officer and Director | 408,000 | 0 | 5,987 | 146,880 | 2,538 | 1,089,305 |
| 2009-04-03 | 2007 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 300,000 | 0 | 0 | 105,600 | 2,079 | 696,148 |
| 2009-04-03 | 2007 | Zbigniew Janowicz, Ph.D. (8) Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 324,409 | 0 | 0 | 81,751 | 18,811 | 589,945 |
| 2008-04-25 | 2007 | Dino Dina, M.D. President, Chief Executive Officer and Director | 400,000 | 0 | 0 | 180,000 | 2,180 | 1,611,913 |
| 2008-04-25 | 2007 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 275,600 | 0 | 0 | 103,626 | 4,787 | 594,668 |
| 2008-04-25 | 2007 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 324,409 | 0 | 0 | 81,751 | 18,811 | 589,945 |
| 2008-04-25 | 2007 | Deborah A. Smeltzer Chief Financial Officer and Vice President, Operations | 302,500 | 0 | 0 | 108,900 | 188 | 754,870 |
| 2008-04-25 | 2007 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 300,000 | 0 | 0 | 105,600 | 2,079 | 696,148 |
| 2007-04-26 | 2006 | Vice President, Preclinical Research | 230,000 | 0 | 0 | 82,340 | 3,248 | 480,604 |
| 2007-04-26 | 2006 | Vice President, Biopharmaceutical Development Gary A. Van Nest, Ph.D. | 240,000 | 0 | 0 | 85,920 | 486 | 533,266 |
| 2007-04-26 | 2006 | Vice President and Chief Scientific Officer Stephen F. Tuck, Ph.D. | 265,000 | 0 | 0 | 94,870 | 3,158 | 585,915 |
| 2007-04-26 | 2006 | Chief Financial Officer and Vice President, Operations Robert L. Coffman, Ph.D. | 275,000 | 0 | 0 | 98,450 | 250 | 640,504 |
| 2007-04-26 | 2006 | President, Chief Executive Officer and Director Deborah A. Smeltzer, | 360,000 | 0 | 0 | 148,500 | 3,244 | 1,324,425 |
| 2006-04-28 | 2005 | Dino Dina, M.D. President and Chief Executive Officer and Director | 338,000 | 162,240 | 0 | 0 | 0 | 500,240 |
| 2006-04-28 | 2004 | Dino Dina, M.D. President and Chief Executive Officer and Director | 325,000 | 130,000 | 0 | 0 | 0 | 455,000 |
| 2006-04-28 | 2003 | Dino Dina, M.D. President and Chief Executive Officer and Director | 300,000 | 120,000 | 0 | 0 | 0 | 420,000 |
| 2006-04-28 | 2005 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 250,000 | 112,000 | 0 | 0 | 0 | 362,000 |
| 2006-04-28 | 2004 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 240,000 | 96,000 | 0 | 0 | 0 | 336,000 |
| 2006-04-28 | 2003 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 218,500 | 65,550 | 0 | 0 | 0 | 284,050 |
| 2006-04-28 | 2005 | Deborah A. Smeltzer Vice President, Operations and Chief Financial Officer | 258,167 | 166,480 | 0 | 0 | 0 | 424,647 |
| 2006-04-28 | 2004 | Deborah A. Smeltzer Vice President, Operations and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2006-04-28 | 2003 | Deborah A. Smeltzer Vice President, Operations and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2006-04-28 | 2005 | Daniel Levitt, M.D., Ph.D. Vice President and Chief Medical Officer | 260,000 | 109,200 | 0 | 0 | 0 | 369,200 |
| 2006-04-28 | 2004 | Daniel Levitt, M.D., Ph.D. Vice President and Chief Medical Officer | 250,000 | 100,000 | 0 | 0 | 0 | 350,000 |
| 2006-04-28 | 2003 | Daniel Levitt, M.D., Ph.D. Vice President and Chief Medical Officer | 104,166 | 0 | 0 | 0 | 0 | 104,166 |
| 2006-04-28 | 2005 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 220,000 | 99,000 | 0 | 0 | 0 | 319,000 |
| 2006-04-28 | 2004 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 212,500 | 85,000 | 0 | 0 | 0 | 297,500 |
| 2006-04-28 | 2003 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 192,600 | 57,780 | 0 | 0 | 0 | 250,380 |
| 2006-04-28 | 2005 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 220,000 | 99,000 | 0 | 0 | 0 | 319,000 |
| 2006-04-28 | 2003 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 192,600 | 57,780 | 0 | 0 | 0 | 250,380 |
| 2006-04-28 | 2004 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 212,500 | 63,750 | 0 | 0 | 0 | 276,250 |
| 2005-04-29 | 2002 | Daniel Levitt, M.D., Ph.D. Vice President and Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2005-04-29 | 2004 | Dino Dina, M.D. President and Chief Executive Officer and Director | 325,000 | 130,000 | 0 | 0 | 0 | 455,000 |
| 2005-04-29 | 2003 | Dino Dina, M.D. President and Chief Executive Officer and Director | 300,000 | 120,000 | 0 | 0 | 0 | 420,000 |
| 2005-04-29 | 2002 | Dino Dina, M.D. President and Chief Executive Officer and Director | 300,000 | 105,000 | 0 | 0 | 0 | 405,000 |
| 2005-04-29 | 2004 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 240,000 | 96,000 | 0 | 0 | 0 | 336,000 |
| 2005-04-29 | 2003 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 218,500 | 65,550 | 0 | 0 | 0 | 284,050 |
| 2005-04-29 | 2002 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 210,000 | 63,000 | 0 | 0 | 0 | 273,000 |
| 2005-04-29 | 2004 | William J. Dawson Former Vice President, Finance & Operations and Chief Financial Officer | 225,000 | 0 | 0 | 0 | 0 | 225,000 |
| 2005-04-29 | 2003 | William J. Dawson Former Vice President, Finance & Operations and Chief Financial Officer | 225,000 | 45,000 | 0 | 0 | 0 | 270,000 |
| 2005-04-29 | 2002 | William J. Dawson Former Vice President, Finance & Operations and Chief Financial Officer | 83,654 | 33,750 | 0 | 0 | 0 | 117,404 |
| 2005-04-29 | 2004 | Daniel Levitt, M.D., Ph.D. Vice President and Chief Medical Officer | 250,000 | 100,000 | 0 | 0 | 0 | 350,000 |
| 2005-04-29 | 2003 | Daniel Levitt, M.D., Ph.D. Vice President and Chief Medical Officer | 104,166 | 0 | 0 | 0 | 0 | 104,166 |
| 2005-04-29 | 2004 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 212,500 | 85,000 | 0 | 0 | 0 | 297,500 |
| 2005-04-29 | 2003 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 192,600 | 57,780 | 0 | 0 | 0 | 250,380 |
| 2005-04-29 | 2002 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 180,000 | 54,000 | 0 | 0 | 0 | 234,000 |
| 2005-04-29 | 2004 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 212,500 | 63,750 | 0 | 0 | 0 | 276,250 |
| 2005-04-29 | 2003 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 192,600 | 57,780 | 0 | 0 | 0 | 250,380 |
| 2005-04-29 | 2002 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 180,000 | 54,000 | 0 | 0 | 0 | 234,000 |
| 2004-04-29 | 2003 | Dino Dina, M.D. President and Chief Executive Officer and Director | 300,000 | 120,000 | 0 | 0 | 0 | 420,000 |
| 2004-04-29 | 2002 | Dino Dina, M.D. President and Chief Executive Officer and Director | 300,000 | 105,000 | 0 | 0 | 0 | 405,000 |
| 2004-04-29 | 2001 | Dino Dina, M.D. President and Chief Executive Officer and Director | 275,000 | 82,500 | 0 | 0 | 0 | 357,500 |
| 2004-04-29 | 2003 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 218,500 | 65,550 | 0 | 0 | 0 | 284,050 |
| 2004-04-29 | 2002 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 210,000 | 63,000 | 0 | 0 | 0 | 273,000 |
| 2004-04-29 | 2001 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 200,000 | 60,000 | 0 | 0 | 0 | 260,000 |
| 2004-04-29 | 2003 | William J. Dawson Vice President, Finance & Operations and Chief Financial Officer | 225,000 | 45,000 | 0 | 0 | 0 | 270,000 |
| 2004-04-29 | 2002 | William J. Dawson Vice President, Finance & Operations and Chief Financial Officer | 83,654 | 33,750 | 0 | 0 | 0 | 117,404 |
| 2004-04-29 | 2001 | William J. Dawson Vice President, Finance & Operations and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2004-04-29 | 2003 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 192,600 | 57,780 | 0 | 0 | 0 | 250,380 |
| 2004-04-29 | 2002 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 180,000 | 54,000 | 0 | 0 | 0 | 234,000 |
| 2004-04-29 | 2001 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 165,000 | 49,500 | 0 | 0 | 0 | 214,500 |
| 2004-04-29 | 2003 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 192,600 | 57,780 | 0 | 0 | 0 | 250,380 |
| 2004-04-29 | 2002 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 180,000 | 54,000 | 0 | 0 | 0 | 234,000 |
| 2004-04-29 | 2001 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 165,000 | 41,250 | 0 | 0 | 0 | 206,250 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
